See the DrugPatentWatch profile for cosentyx

Based on the information available, it is not recommended to lower the dose of Cosentyx (secukinumab) without consulting a healthcare professional, as it may lead to a worsening of the disease. Cosentyx is a prescription medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by targeting a specific protein in the body that contributes to inflammation and related symptoms [1].

The safety and efficacy of Cosentyx are based on the approved dosages, and any changes to the dosage should be made under the guidance of a healthcare provider [1]. Lowering the dose without proper medical supervision could result in suboptimal treatment, leading to disease progression or worsening symptoms.

Furthermore, it is essential to consider that each individual's response to medication may vary. Factors such as age, weight, liver and kidney function, and other health conditions can influence how a person reacts to a particular drug [2]. Therefore, any modifications to the treatment plan should be tailored to the patient's specific needs and closely monitored by a healthcare professional.

In summary, based on the available information, it is not advisable to lower the Cosentyx dose without consulting a healthcare provider, as it may result in worsening of the disease. Individual responses to medication may vary, and any changes to the treatment plan should be made under medical supervision [1][2].

Sources:
[1] Cosentyx (secukinumab) [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf
[2] Mayo Clinic. Medication dosage: Why it's important to get it right. https://www.mayoclinic.org/diseases-conditions/drug-safety/in-depth/medication-dosage/art-20046679